EpiEndo Pharmaceuticals

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of oral drugs called Barriolides™ to treat chronic respiratory diseases. Its lead candidate, glasmacinal, is a non-antibiotic macrolide designed to reduce inflammation and enhance host defense responses in COPD patients without promoting antimicrobial resistance. The company targets the high unmet needs of patients suffering from chronic obstructive pulmonary disease and other inflammatory conditions.